Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Showing results for

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.

Bijukchhe SM. et al, (2026), Lancet Infect Dis

Genome-scale functional mapping of the mammalian whole brain with in vivo Perturb-seq.

Shi T. et al, (2026)

Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer's disease.

Woffindale C. et al, (2026), Mol Ther Nucleic Acids, 37

Predicting how perturbations reshape cellular trajectories with PerturbGen

Chi Hao Ly K. et al, (2026)

Crossing the finish line towards a disease-modifying treatment for Angelman syndrome.

Judson MC. et al, (2026), J Neurodev Disord, 18

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.

Hausdorff WP. et al, (2026), Vaccine, 75

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Tembo G. et al, (2026), Vaccine, 75

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Cheliotis KS. et al, (2026), Vaccine, 75

comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.

Shen Y. et al, (2026), Cell Stem Cell, 33, 421 - 437.e7

Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1.

González-Martínez I. et al, (2026), Am J Hum Genet, 113, 529 - 547